Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.

Trial Details

NCT ID
NCT06284590
Phase
PHASE2
Sponsor
Philogen S.p.A.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • L19IL2
  • L19TNF
  • L19IL2/L19TNF
  • KEYTRUDA®
Locations (sample)
  • Hartford, Connecticut, United States|41.76371,-72.68509
  • New York, New York, United States|40.71427,-74.00597
  • Essen, Germany, Germany|51.45657,7.01228
  • Freiburg im Breisgau, Germany, Germany|47.9959,7.85222
  • Kiel, Germany, Germany|54.32133,10.13489

Key Eligibility Criteria

  • The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
  • Be \> or = 18 years of age on day of signing informed consent.
  • Participant with histologically or cytologically confirmed diagnosis of unresectable metastatic melanoma at stage III B, C, D or IV M1a (AJCC 8th e…
  • However, patients with symptomatic or rapidly enlarging/bleeding brain lesions are excluded. Patients with acral lentiginous melanoma are eligible …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →